09:36 AM EST - Helix BioPharma Corp. : Provided a corporate update on initiatives that were undertaken by the Company in 2021. Despite the challenges brought about by the COVID-19 pandemic, 2021 was a productive year for the Company. During the second half of 2021, the Company initiated efforts to validate Helix and its lead clinical program with external stakeholders to bring in an outside perspective to the company's strategy and future. Helix BioPharma Corp.
shares T.HBP are trading unchanged at $0.30.
